secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2026-08-04T11:09:08+00:00
Accession:  0001193125-26-331522
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics Q2 net loss $122.7M; first patient dosed in BEAM-302 pivotal trial
--------------------------------------------------------------------------------

- Net loss of $122.7M ($1.18 per share) vs $102.1M loss in Q2 2025; R&D expenses $95.1M.
- First patient dosed in global pivotal cohort of BEAM-302 for AATD; updated data at ERS Congress Sept 2026.
- Dosing complete for all patients in BEACON trial of risto-cel for SCD; BLA submission expected as early as year-end 2026.
- FDA cleared IND for BEAM-304 in PKU; clinical start-up activities underway.
- Cash $1.2B as of June 30, 2026; with $200M from Sixth Street, runway into mid-2029.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/0001193125-26-331522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000119312526331522/beam-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-331522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer